Gary Hammer, M.D., Ph.D.
Gary D. Hammer, M.D., Ph.D. is a Professor in the Departments of Internal Medicine (Metabolism, Endocrinology & Diabetes), Cell & Developmental Biology, and Molecular & Integrative Physiology at the University of Michigan (UofM). Before arriving in Michigan in 1999, he obtained his M.D. and Ph.D. in Neuroscience from Tufts University and completed his residency in Internal Medicine followed by a clinical fellowship in Endocrinology and a post-doctoral fellowship with Holly Ingraham at the University of California at San Francisco. He currently serves as the Director of the Endocrine Oncology Program in the Comprehensive Cancer Center at UofM where he holds the Millie Schembechler Professorship in Adrenal Cancer. He has brokered the recent renaissance of the current Michigan team of adrenal scientists that includes a who's who in the clinical and basic study of adrenal disease. He received the UofM Jerome Conn Award for Outstanding Research in Internal Medicine, the Endocrine Society Edwin B. Astwood Award for Outstanding Research in Endocrinology and is a member of the American Society for Clinical Investigation and Association of American Physicians. He is the editor of three textbooks: Adrenocortical Carcinoma: Basic Science and Clinical Concepts (Springer 2011), Pathophysiology of Disease: An Introduction to Clinical Medicine (Harper Row, 2014) and Genetics Steroid Disorders (Elsevier, 2014). In addition to being a founding organizer of the biennial International Adrenal Cancer Symposium, he also is a member of the coordinating team of the biennial International Adrenal Meetings and has served in numerous capacities across the tripartite constituencies of the Endocrine Society including Chair of the Student Affairs Committee, Chair of the Mentoring Task Force, Basic Science Chair of the Annual Meeting Trainee Day, Council Member at Large and Society Ambassador to King Edward Memorial Hospital in Mumbai India as part of the inaugural Endocrine Society Ambassador Exchange Program. Most recently he has served as the Clinical Research Chair of the 2016 Endocrine Society Annual Meeting and will be the Overall Chair of the 2017 Annual Meeting. Research projects in his own laboratory are aimed at elucidating the mechanisms by which growth factor signaling and transcriptional programs initiate adrenal-specific growth and differentiation with an emphasis on dysregulated adrenocortical stem cells in development and cancer. He is a co-founder of the company MILLENDO that focuses on therapies for adrenal cancer. Collaborative work with colleagues has led to the development of new national and international therapeutic trials with biological-based therapies for adrenal cancer that target the molecular defects in cancer while sparing normal tissue.
The long range objective of Dr. Hammer¡¦s laboratory is to understand the cellular and molecular mechanisms by which signaling pathways and downstream transcription factors coordinate the specification of adrenocortical cells within the adrenal gland